Novo Holdings A S Sells 327,919 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Novo Holdings A S lessened its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 22.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,122,581 shares of the company’s stock after selling 327,919 shares during the quarter. Novo Holdings A S owned about 3.41% of Lexeo Therapeutics worth $10,148,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LXEO. Values First Advisors Inc. purchased a new position in Lexeo Therapeutics during the 3rd quarter worth $67,000. Rhumbline Advisers increased its holdings in shares of Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after acquiring an additional 3,627 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Lexeo Therapeutics by 12.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock valued at $510,000 after purchasing an additional 3,483 shares during the last quarter. RA Capital Management L.P. purchased a new position in shares of Lexeo Therapeutics in the 1st quarter valued at approximately $10,364,000. Finally, Artal Group S.A. grew its position in Lexeo Therapeutics by 32.9% during the 1st quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after purchasing an additional 198,281 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO opened at $9.50 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.38 and a quick ratio of 9.38. The firm’s 50 day simple moving average is $10.05 and its 200-day simple moving average is $12.67. Lexeo Therapeutics, Inc. has a 12 month low of $7.86 and a 12 month high of $22.33. The stock has a market capitalization of $314.07 million and a price-to-earnings ratio of -0.65.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.64). Analysts expect that Lexeo Therapeutics, Inc. will post -2.74 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LXEO shares. HC Wainwright reduced their price objective on Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Chardan Capital reissued a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Friday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.14.

Insider Buying and Selling

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total value of $40,500.00. Following the sale, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at approximately $977,629.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 15,000 shares of company stock valued at $151,400. 4.50% of the stock is owned by company insiders.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.